Free tool
FAERS Monitor: Simulect
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103764 or its brand name (Simulect, Basiliximab). Reports on generic versions are filed under their own applications.
Reports
11,930
Serious
11,655
98% of reports
Hospitalization
4,993
Death reported
2,541
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,081
- cytomegalovirus infection929
- drug ineffective918
- transplant rejection874
- kidney transplant rejection786
- pyrexia623
- product use in unapproved indication542
- blood creatinine increased522
- diarrhoea520
- renal impairment467
- acute kidney injury462
- anaemia457
- thrombotic microangiopathy447
- multiple organ dysfunction syndrome439
- sepsis437
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 87 |
| 2005 | 69 |
| 2006 | 79 |
| 2007 | 105 |
| 2008 | 180 |
| 2009 | 172 |
| 2010 | 201 |
| 2011 | 314 |
| 2012 | 335 |
| 2013 | 305 |
| 2014 | 462 |
| 2015 | 447 |
| 2016 | 532 |
| 2017 | 622 |
| 2018 | 864 |
| 2019 | 1,086 |
| 2020 | 1,009 |
| 2021 | 801 |
| 2022 | 732 |
| 2023 | 799 |
| 2024 | 1,237 |
| 2025 | 901 |
| 2026 | 589 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| kidney transplant rejectionSignal | 786 | 345.1 | 320.4 | 225,324 |
| transplant rejectionSignal | 874 | 215.7 | 201.5 | 166,273 |
| cytomegalovirus infectionSignal | 929 | 104.3 | 97.9 | 89,725 |
| thrombotic microangiopathySignal | 447 | 84.7 | 77.2 | 35,216 |
| multiple organ dysfunction syndromeSignal | 439 | 27.7 | 25.3 | 11,128 |
| blood creatinine increasedSignal | 522 | 14.2 | 13.1 | 6,362 |
| renal impairmentSignal | 467 | 9.9 | 9.0 | 3,699 |
| sepsisSignal | 437 | 6.9 | 6.3 | 2,215 |
| acute kidney injurySignal | 462 | 5.3 | 4.9 | 1,630 |
| anaemiaSignal | 457 | 4.2 | 3.9 | 1,132 |
| product use in unapproved indicationSignal | 542 | 3.9 | 3.6 | 1,158 |
| pyrexiaSignal | 623 | 3.2 | 2.9 | 942 |
| off label useSignal | 1,081 | 2.2 | 2.1 | 717 |
| diarrhoea | 520 | 1.4 | 1.3 | 66 |
| drug ineffective | 918 | 1.2 | 1.2 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.